1. Home
  2. MEGL vs XLO Comparison

MEGL vs XLO Comparison

Compare MEGL & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magic Empire Global Limited

MEGL

Magic Empire Global Limited

N/A

Current Price

$0.16

Market Cap

50.3M

Sector

Finance

ML Signal

N/A

XLO

Xilio Therapeutics Inc.

N/A

Current Price

$8.19

Market Cap

56.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MEGL
XLO
Founded
2016
2016
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.3M
56.9M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
MEGL
XLO
Price
$0.16
$8.19
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $18.00
AVG Volume (30 Days)
★ 703.6K
13.1K
Earning Date
11-10-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $43,766,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$23.90
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 589.88
52 Week Low
$0.16
$0.46
52 Week High
$1.54
$24.64

Technical Indicators

Market Signals
Indicator
MEGL
XLO
Relative Strength Index (RSI) 13.11 43.24
Support Level N/A $7.37
Resistance Level $1.35 $9.21
Average True Range (ATR) 0.10 0.66
MACD -0.05 -0.06
Stochastic Oscillator 0.69 44.59

Price Performance

Historical Comparison
MEGL
XLO

About MEGL Magic Empire Global Limited

Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The company's offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.

Share on Social Networks: